A vs ABBV Stock Comparison

Scores Breakdown

Metric	A	ABBV
📈 Growth	18/30	15/30
💰 Profitability	16/20	16/20
🏦 Financial Health	7/20	12/20
💵 Valuation	9/20	12/20
⚠️ Risk (lower is better)	7/10	6/10
Overall Score	53/100	59/100

Side-by-Side Summaries

A Analysis	ABBV Analysis
📈 Growth & Financial Trajectory Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability. 💰 Margins & Cash Flow Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters. Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B. Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions. 🛡️ Balance Sheet & Liquidity Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows. ⚠️ Key Drivers & Risks Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation. Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.	📈 Growth & Financial Trajectory 8 quarters show a largely rising topline: 2024Q1 to 2026Q1 Revenues rise from about $12.31B to $15.00B (+≈22%). Net income attributable to parent falls from ~$1.29B to ~$0.70B, though peaks around ~$1.86B in 2025Q2–Q3, with 2025Q4 at ~$1.82B. The trend is mixed: topline strength persists, but bottom-line profitability weakens into 2026Q1. 💰 Margins & Cash Flow Gross margins remain high, broadly ~70–79%, reflecting a durable product mix. Operating leverage remains healthy as volumes expand. Net cash flow from operating activities stays robust, typically around $5.1B–$5.3B per quarter; investing activity is negative (capex/activity), and financing flows cause periodic swings. 🛡️ Balance Sheet & Liquidity Total assets hover near the mid-to-upper hundreds of billions with liabilities that verge on or exceed assets in some periods, and equity attributable to the parent is often negative (reflecting buybacks). The firm generates solid operating cash flow that supports liquidity despite leverage. Long-term debt runs in the mid-$60B range in recent periods, with current liabilities ~$39–$44B. ⚠️ Key Drivers & Risks Drivers: Robust pharma demand and a durable high-margin mix; ongoing pipeline progress. Risks: Patent/regulatory pressures; elevated leverage and sensitivity to interest rates; potential valuation volatility.

A Analysis

ABBV Analysis

📈 Growth & Financial Trajectory

Over eight quarters, Revenues rose from about $1.66B to $1.84B, a positive trend, with a mid-2025 dip. Net income fluctuated from $308M–$434M, ending near $339M in 2026 Q2. The sequence shows top-line resilience but earnings volatility, implying improving mix or cost management but not a steady uplift in profitability.

💰 Margins & Cash Flow

Gross Margin is generally in the mid-50s percentile, peaking around 63% in 2024 Q2 and typical ~50–55% in other quarters.
Operating Margin has run in the high-teens to low-20s percent range on Revenues of ~$1.6–$1.8B.
Operating cash flow remains positive across quarters (roughly $0.27–$0.55B), while investing cash flow is negative (capital outlays), and financing cash flow is often negative, reflecting debt/return actions.

🛡️ Balance Sheet & Liquidity

Total Assets (~~$11–$13B) exceed Liabilities (~~$4.8–$6B) with Equity frequently negative, signaling balance-sheet rehabilitation needs. Current assets vs current liabilities suggests solid liquidity (working capital positive); long-term debt remains a meaningful load but generally manageable within cash flows.

⚠️ Key Drivers & Risks

Drivers: Life sciences capex & instrument upgrades; continued demand for laboratory testing and automation.
Risks: Earnings volatility from cyclic lab-spend; structural negative equity raises valuation sensitivity and balance-sheet risk.

📈 Growth & Financial Trajectory

8 quarters show a largely rising topline: 2024Q1 to 2026Q1 Revenues rise from about $12.31B to $15.00B (+≈22%). Net income attributable to parent falls from ~$1.29B to ~$0.70B, though peaks around ~$1.86B in 2025Q2–Q3, with 2025Q4 at ~$1.82B. The trend is mixed: topline strength persists, but bottom-line profitability weakens into 2026Q1.

💰 Margins & Cash Flow

Gross margins remain high, broadly ~70–79%, reflecting a durable product mix. Operating leverage remains healthy as volumes expand. Net cash flow from operating activities stays robust, typically around $5.1B–$5.3B per quarter; investing activity is negative (capex/activity), and financing flows cause periodic swings.

🛡️ Balance Sheet & Liquidity

Total assets hover near the mid-to-upper hundreds of billions with liabilities that verge on or exceed assets in some periods, and equity attributable to the parent is often negative (reflecting buybacks). The firm generates solid operating cash flow that supports liquidity despite leverage. Long-term debt runs in the mid-$60B range in recent periods, with current liabilities ~$39–$44B.

⚠️ Key Drivers & Risks

Drivers: Robust pharma demand and a durable high-margin mix; ongoing pipeline progress.
Risks: Patent/regulatory pressures; elevated leverage and sensitivity to interest rates; potential valuation volatility.

Similar Companies

AMAT Score: 80 AME Score: 81 ANET Score: 84 GOOGL Score: 78 TMO Score: 75 WAT Score: 78

Top Rated Companies

View Top 20 →

MU "MICRON TECHNOLOGY INC"

AVGO "Broadcom Inc."

KMI "KINDER MORGAN, INC."

MNST "Monster Beverage Corp"

NEM "NEWMONT Corp /DE/"